Nutra Pharma delays Q2 10-Q filing, citing need for more time to finalize financials

• Nutra Pharma filed a Form 12b-25 to delay its Form 10-Q for the quarter ended June 30, 2026.
• Management cited the need for more time with auditors to prepare financial information for the quarterly report.
• The filing targets submission within five calendar days of the original due date.
• The notice flagged no expected significant change in results from the comparable prior-year period.
• The late-filing notification was signed Aug. 14, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nutra Pharma Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-038022), on August 14, 2026, and is solely responsible for the information contained therein.